Dr. Kevin Fahey Appointed to illumiSonics Board of Directors

OrthoNext Digital Platform for the JuniOrtho Plating System Receives FDA Clearance

“Together, OrthoNext and the JuniOrtho Plating System provide a complete solution for surgeons looking for a plating system to address the specific demands of advanced deformity and trauma reconstruction of the lower extremities in the pediatric population,” said Orthofix President of Global Orthopedics Paul Gonsalves.

SonarMed, New Pediatric Monitor Alerts Clinicians To Potential Airway Obstructions During Ventilation Launched

"The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded," said Jamie W. Powers, M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California.

February 10, 2021

illumiSonics Inc., is a medical tissue imaging company. Today they announced the appointment of Kevin Fahey, Ph.D., to the Board of Directors. The company has taken this action in anticipation of its growth and the commercial introduction of its proprietary Photo Acoustic Remote Sensing (PARS) tissue imaging platform.

Dr. Kevin Fahey brings new skills and will help strengthen the board of directors.

“Dr. Fahey brings commercial imaging domain expertise and industry-specific relationships to fully enable the power and unique capabilities of PARS as we fundamentally change the way the world looks at living tissue,” said Rocky Ganske CEO.

“PARS brings all of the valuable imaging of traditional photoacoustics, uniquely without the need for an interface. This capability opens several clinical applications not possible today with any other commercial imaging technology. We believe this creates a number of product and partnering opportunities for illumiSonics, and I am looking forward to participating,” said Dr. Fahey.

Dr. Fahey held executive positions at Xradia (acquired by ZEISS) and FEI (acquired by ThermoFisher), and at both large and small companies. In every case, he drove dramatic growth, creating new business lines and implementing integrated sales and marketing channels that drove rapid increases in sales. Dr. Fahey holds a Ph.D. in Materials Science and Engineering from Stanford University and a B.S. in Physics from the Massachusetts Institute of Technology.

illumiSonics’ proprietary PARS photoacoustic remote sensing technology is a revolution in optical imaging. Like traditional photoacoustic imaging, PARS measures optical absorption and is capable of providing functional and molecular imaging of anything that can absorb light. Traditional photoacoustic imaging has been constrained by the need to have contact with targeted tissues, the size of transducers and an inability to easily integrate with other optical imaging techniques. PARS is the first fully optical, non-contact photoacoustic imaging technology. This allows PARS to maintain all of the advantages of photoacoustic imaging while addressing its shortcomings, which provides incredible flexibility in how it can be deployed.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles